Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Current & emerging treatments for patients with triple-class refractory multiple myeloma

Enrique Ocio • 9 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T Selinexor Teclistamab

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, outlines current and emerging treatment strategies for patients with triple-class refractory multiple myeloma, which currently include belantamab mafodotin and selinexor. The recent introduction and development of CAR-T therapy and bispecific antibodies in this setting is changing the treatment landscape of patients with triple-class refractory disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Enrique Ocio

2:18
Efficacy and safety results from the ANCHOR trial
Enrique Ocio • 29 Sep 2023
2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals